Opioid Antagonist: Past, Present & Future

Mohan Sindhwani, MD, Medical Director of the Opioid Antidote/Device division at Emergent, has several years of experience developing medical strategy and communications, providing scientific training on clinical disease/drug information across a number of pain specialty areas, and he is currently responsible for building brand advocacy with thought leaders, pharmacists, public interest groups, among many other critical stakeholders and presenting technical information on a peer-to-peer basis for opioid-related mortality and opioid antagonist. His clinical medicine experience in general surgery led to his successful tenure as a trauma lead investigator and postdoctoral research in vascular neurosurgery, all of which have driven his value for patient centric care, medical investigation, and evidence-based communication. He has published several peer-reviewed articles.

The presentation will review the role of opioid antagonists within the changing landscape of the opioid crisis. Access and education surrounding opioid antagonist remain key issues to equipping medical and non-medical personnel in administering naloxone.

Learning Objectives:

  1. Gain understanding of increase in opioid-related mortality while learning about the use of naloxone and the various options
  2. Improve participants’ ability to make informed decisions regarding naloxone use
  3. Discuss evidence around common misconceptions about naloxone.

Relevant to the content of this educational activity, the following individual(s) have conflict(s) with ineligible companies to disclose. 

  • Mohan Sindhwani, MD, Speaker, is a full- or part-time employee of Emergent BioSolutions. Dr. Sindhwani’s relevant financial relationship has been mitigated, and his participation in this accredited education cannot be resolved. CME credit is not available for his presentation.